Great Basin Scientific Inc. (fka GBSNQ)

[L-Back]

When it is all said and done pennies and nickel won't mean chit down here been saying it and will keep saying it...


What Analyst’s have to say Great Basin Scientific Inc?


http://cwruobserver.com/2016/01/25/what-analysts-have-to-say-great-basin-scientific-inc/

On January 21, 2016, Great Basin Scientific Inc (GBSN) a molecular diagnostics company, announced that as of 5 p.m. the Company has converted all outstanding Series C Warrants into shares of its common stock and therefore now has 75.5 million shares of common stock issued and outstanding, and has no remaining unconverted Series C Warrants.

The shares of Great Basin Scientific Inc (NASDAQ:GBSN) currently has mean rating of 2.50 while Zero analysts have recommended the shares as “BUY”, one recommended as “OUTPERFORM” and one recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Dec-15 is 1.31 million by 1 analysts. The means estimate of sales for the year ending Dec-16 is 2.90 million by 1 analysts.

The mean price target for the shares of Great Basin Scientific Inc (GBSN) is at 581.40 while the highest price target suggested by the analysts is 600.00 and low price target is 562.00. The mean price target is calculated keeping in view the consensus of 2 brokerage firms.

The average estimate of EPS for the current year is fixed at -192.60 by 1.00 analysts.

The next one year’s EPS estimate is set at -228.60 by 1.00 analysts while a year ago the analysts suggested the company’s EPS at -192.60.

In its latest quarter ended on 30th September 2015, Great Basin Scientific Inc (GBSN) reported earnings of $-9.00. The posted earnings topped the analyst’s consensus by $25.20 with the surprise factor of 73.70%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections. The company’s platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman.